XNASMYNZ
Market cap9mUSD
Dec 23, Last price
4.96USD
1D
-25.75%
1Q
2,392.46%
IPO
-50.35%
Name
Mainz Biomed NV
Chart & Performance
P/E
—
P/S
11.09
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
895k
+69.00%
Net income
-26m
L-0.59%
CFO
-22m
L+48.54%
Earnings
Apr 07, 2025
Profile
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 895 69.00% | 530 -8.22% | 577 16.98% | ||
Cost of revenue | 27,198 | 26,819 | 10,277 | ||
Unusual Expense (Income) | |||||
NOPBT | (26,302) | (26,289) | (9,700) | ||
NOPBT Margin | |||||
Operating Taxes | 65 | 377 | |||
Tax Rate | |||||
NOPAT | (26,302) | (26,354) | (10,077) | ||
Net income | (26,296) -0.59% | (26,453) 119.12% | (12,072) 1,262.29% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 6,393 | 23,866 | 10,425 | ||
BB yield | -33.93% | -23.74% | -13.91% | ||
| Debt | |||||
Debt current | 5,225 | 1,326 | 249 | ||
Long-term debt | 3,650 | 3,147 | 2,771 | ||
Deferred revenue | |||||
Other long-term liabilities | 727 | ||||
Net debt | 1,804 | (12,669) | (5,708) | ||
| Cash flow | |||||
Cash from operating activities | (21,939) | (14,770) | (3,220) | ||
CAPEX | (1,199) | (658) | (17) | ||
Cash from investing activities | (1,899) | (658) | 1,203 | ||
Cash from financing activities | 14,227 | 23,943 | 10,611 | ||
FCF | 771,980 | (827,239) | (10,271) | ||
| Balance | |||||
Cash | 7,071 | 17,142 | 8,728 | ||
Long term investments | |||||
Excess cash | 7,026 | 17,115 | 8,699 | ||
Stockholders' equity | (48,258) | (24,735) | (6,765) | ||
Invested Capital | 59,655 | 42,060 | 15,700 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 16,242 | 14,157 | 7,211 | ||
Price | 1.16 -83.66% | 7.10 -31.67% | 10.39 | ||
Market cap | 18,841 -81.26% | 100,518 34.17% | 74,921 | ||
EV | 20,645 | 87,849 | 69,213 | ||
EBITDA | (25,436) | (25,909) | (9,630) | ||
EV/EBITDA | |||||
Interest | 810 | 289 | 339 | ||
Interest/NOPBT | |||||